4582

SymBio Pharmaceuticals Limited

シンバイオ製薬株式会社
Pharmaceutical
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
← Companies
Price
¥78
Market Cap
¥4.6B
Ent. Value
—
Net Cash est
—
Shares Out.
59.5M
P / E
—
EV / EBIT
—
P / Book
5.02×
P / NCAV
3.78×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥1.3B ¥2.5B ¥5.6B ¥10.0B ¥8.3B
Cost of Sales ¥360M ¥580M ¥1.2B ¥2.4B —
Gross Profit ¥947M ¥1.9B ¥4.4B ¥7.6B ¥5.8B
SG&A ¥5.4B ¥5.8B ¥5.2B ¥5.6B ¥4.8B
Operating Income ¥-4.4B ¥-3.9B ¥-812M ¥2.0B ¥1.0B
Non-Operating Income ¥31M ¥225M ¥133M ¥139M ¥17M
Interest Income ¥4M ¥32M ¥12M ¥0M ¥0M
Non-Operating Expenses ¥238M ¥37M ¥57M ¥103M ¥32M
Ordinary Income ¥-4.6B ¥-3.7B ¥-736M ¥2.0B ¥1.0B
Pre-tax Income ¥-4.7B ¥-3.8B ¥-1.2B ¥2.1B ¥1.0B
Income Taxes ¥28M ¥27M ¥767M ¥927M ¥-1.0B
Current Tax ¥33M ¥27M ¥23M ¥396M ¥245M
Deferred Tax ¥-6M — ¥745M ¥531M ¥-1.3B
Net Income (owners) ¥-4.8B ¥-3.8B ¥-2.0B ¥1.2B ¥2.0B
Comprehensive Income ¥-4.8B ¥-3.8B ¥-2.0B ¥1.2B —
EBITDA — — ¥-716M ¥2.1B ¥1.1B
EPS ¥-95.12 ¥-85.00 ¥-49.19 ¥30.20 ¥53.04
Shares Outstanding 59.5M 45.8M 42.2M 39.5M 38.5M
Shares Issued (total) 59.6M 45.9M 42.3M 39.6M 38.5M
Treasury Shares 0.1M 0.1M 0.1M 0.1M —